You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameButalbital
Accession NumberDB00241  (APRD00266)
TypeSmall Molecule
GroupsApproved, Illicit
Description

Butalbital, 5-allyl-5-isobutylbarbituric acid, is a barbiturate with an intermediate duration of action. It has the same chemical formula as talbutal but a different structure. Butalbital is often combined with other medications, such as acetaminophen or aspirin, and is commonly prescribed for the treatment of pain and headache. [Wikipedia]

Structure
Thumb
Synonyms
SynonymLanguageCode
5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trioneNot AvailableNot Available
5-Allyl-5-(2-methylpropyl)barbituric acidNot AvailableNot Available
5-Allyl-5-(2'-methyl-N-propyl) barbituric acidNot AvailableNot Available
5-Allyl-5-isobutyl-2,4,6(1H,3H,5H)-pyrimidinetrioneNot AvailableNot Available
5-Allyl-5-isobutyl-pyrimidine-2,4,6-trioneNot AvailableNot Available
5-Allyl-5-isobutylbarbituric acidNot AvailableNot Available
5-isobutyl-5-allylbarbituric acidNot AvailableNot Available
allylbarbitalNot AvailableNot Available
allylbarbitoneNot AvailableNot Available
Allylbarbituric acidNot AvailableNot Available
ButalbarbitalNot AvailableNot Available
ButalbitalumNot AvailableNot Available
Iso-butylallylbarbituric acidNot AvailableNot Available
ItobarbitalNot AvailableNot Available
TetrallobarbitalNot AvailableNot Available
Prescription ProductsNot Available
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International Brands
NameCompany
SandoptalNot Available
Brand mixtures
Brand NameIngredients
AlagesicCaffeine + Butalbital + Acetaminophen
BUPAPButalbital + Acetaminophen
ButapapButalbital + Acetaminophen
CapacetCaffeine + Butalbital + Acetaminophen
Esgic-PlusCaffeine + Butalbital + Acetaminophen
Fiorinal C1/2 CapAcetylsalicylic Acid + Butalbital + Caffeine + Codeine Phosphate
Fiorinal C1/4 CapAcetylsalicylic Acid + Butalbital + Caffeine + Codeine Phosphate
Fiorinal TabAcetylsalicylic Acid + Butalbital + Caffeine
ORBIVANCaffeine + Butalbital + Acetaminophen
PhrenilinButalbital + Acetaminophen
Ratio-TecnalAcetylsalicylic Acid + Butalbital + Caffeine
Ratio-Tecnal C 1/2Acetylsalicylic Acid + Butalbital + Caffeine + Codeine Phosphate
Ratio-Tecnal C1/4Acetylsalicylic Acid + Butalbital + Caffeine + Codeine Phosphate
Trianal CapsulesAcetylsalicylic Acid + Butalbital + Caffeine
Trianal TabletAcetylsalicylic Acid + Butalbital + Caffeine
Trianal-C 1/2 CapsuleAcetylsalicylic Acid + Butalbital + Caffeine + Codeine Phosphate
SaltsNot Available
CategoriesNot Available
CAS number77-26-9
WeightAverage: 224.2563
Monoisotopic: 224.116092388
Chemical FormulaC11H16N2O3
InChI KeyUZVHFVZFNXBMQJ-UHFFFAOYSA-N
InChI
InChI=1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)
IUPAC Name
5-(2-methylpropyl)-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione
SMILES
CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentBarbituric acid derivatives
Alternative Parents
Substituents
  • Barbiturate
  • Ureide
  • 1,3-diazinane
  • Urea
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationUsed in combination with acetaminophen or aspirin and caffeine for its sedative and relaxant effects in the treatment of tension headaches, migraines, and pain.
PharmacodynamicsButalbital is a short to intermediate-acting barbiturate. Barbiturates act as nonselective depressants of the central nervous system (CNS), capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma. In sufficiently high therapeutic doses, barbiturates induce anesthesia.
Mechanism of actionButalbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
AbsorptionWell absorbed from the gastrointestinal tract and is expected to distribute to most tissues in the body.
Volume of distributionNot Available
Protein binding45%
Metabolism

Hepatic, although most of the dose is eliminated via the kidney (59 to 88%). Urinary excretion products included parent drug (about 3.6% of the dose), 5-isobutyl-5-(2,3-dihydroxypropyl) barbituric acid (about 24% of the dose), 5-allyl-5(3-hydroxy-2-methyl-1-propyl) barbituric acid (about 4.8%).

Route of eliminationNot Available
Half life35 hours
ClearanceNot Available
ToxicitySymptoms of acute barbiturate poisoning include drowsiness, confusion, coma, respiratory depression, hypotension, and shock.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9112
Blood Brain Barrier+0.9703
Caco-2 permeable-0.5936
P-glycoprotein substrateNon-substrate0.5365
P-glycoprotein inhibitor IInhibitor0.5179
P-glycoprotein inhibitor IINon-inhibitor0.9678
Renal organic cation transporterNon-inhibitor0.9331
CYP450 2C9 substrateNon-substrate0.7999
CYP450 2D6 substrateNon-substrate0.8708
CYP450 3A4 substrateNon-substrate0.6804
CYP450 1A2 substrateNon-inhibitor0.8535
CYP450 2C9 substrateNon-inhibitor0.8768
CYP450 2D6 substrateNon-inhibitor0.9324
CYP450 2C19 substrateNon-inhibitor0.8354
CYP450 3A4 substrateNon-inhibitor0.9074
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9626
Ames testNon AMES toxic0.5716
CarcinogenicityNon-carcinogens0.8861
BiodegradationNot ready biodegradable0.9833
Rat acute toxicity3.0783 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9898
hERG inhibition (predictor II)Non-inhibitor0.9711
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage formsNot Available
Prices
Unit descriptionCostUnit
Butalbital powder3.83USD g
Butalbital compound tablet1.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point138.5 °CPhysProp
water solubility1700 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.23 mg/mLALOGPS
logP1.47ALOGPS
logP1.59ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)8.48ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.27 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity58.05 m3·mol-1ChemAxon
Polarizability22.42 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferenceNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AcetaminophenBarbiturates may increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.
AmlodipineBarbiturates may increase the metabolism of Calcium Channel Blockers.
AmrinoneBarbiturates may increase the metabolism of Calcium Channel Blockers.
AripiprazoleCYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
BepridilBarbiturates may increase the metabolism of Calcium Channel Blockers.
BuprenorphineCNS Depressants may enhance the CNS depressant effect of Buprenorphine.
BusulfanAcetaminophen may increase the serum concentration of Busulfan.
ButabarbitalMay increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.
ButethalMay increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.
CarbamazepineMay increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.
ChloramphenicolBarbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.
DasatinibAcetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen.
DofetilideCYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.
DoxycyclineBarbiturates may decrease the serum concentration of Doxycycline.
DoxylamineMay enhance the CNS depressant effect of CNS Depressants.
DronabinolMay enhance the CNS depressant effect of CNS Depressants.
DroperidolMay enhance the CNS depressant effect of CNS Depressants.
EtoposideBarbiturates may decrease the serum concentration of Etoposide.
FelbamateBarbiturates may decrease the serum concentration of Felbamate. Felbamate may increase the serum concentration of Barbiturates.
FelodipineBarbiturates may increase the metabolism of Calcium Channel Blockers.
FlunarizineBarbiturates may increase the metabolism of Calcium Channel Blockers.
GabapentinBarbiturates may increase the metabolism of Calcium Channel Blockers.
GriseofulvinBarbiturates may decrease the serum concentration of Griseofulvin.
HeptabarbitalMay increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.
HexobarbitalMay increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.
HydrocodoneCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
HydroxyzineMay enhance the CNS depressant effect of Barbiturates.
ImatinibAcetaminophen may enhance the hepatotoxic effect of Imatinib.
IsoniazidMay enhance the adverse/toxic effect of Acetaminophen.
IsradipineBarbiturates may increase the metabolism of Calcium Channel Blockers.
LamotrigineBarbiturates may increase the metabolism of Calcium Channel Blockers.
LercanidipineBarbiturates may increase the metabolism of Calcium Channel Blockers.
LomitapideCYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.
Magnesium SulfateBarbiturates may increase the metabolism of Calcium Channel Blockers.
MethohexitalMay increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.
MethotrimeprazineCNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.
MetyraponeMay increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.
MetyrosineCNS Depressants may enhance the sedative effect of Metyrosine.
MianserinMay enhance the CNS depressant effect of Barbiturates. Mianserin may diminish the therapeutic effect of Barbiturates. Barbiturates may decrease the serum concentration of Mianserin.
MipomersenAcetaminophen may enhance the hepatotoxic effect of Mipomersen.
MirtazapineCNS Depressants may enhance the CNS depressant effect of Mirtazapine.
NabiloneMay enhance the CNS depressant effect of CNS Depressants.
NicardipineBarbiturates may increase the metabolism of Calcium Channel Blockers.
NimodipineBarbiturates may increase the metabolism of Calcium Channel Blockers.
NisoldipineBarbiturates may increase the metabolism of Calcium Channel Blockers.
NitrendipineBarbiturates may increase the metabolism of Calcium Channel Blockers.
Nitric OxideMay enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.
OrphenadrineCNS Depressants may enhance the CNS depressant effect of Orphenadrine.
PentobarbitalMay increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.
PerampanelMay enhance the CNS depressant effect of CNS Depressants.
PerhexilineBarbiturates may increase the metabolism of Calcium Channel Blockers.
PimozideCYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.
PramipexoleCNS Depressants may enhance the sedative effect of Pramipexole.
PrenylamineBarbiturates may increase the metabolism of Calcium Channel Blockers.
PrilocaineMethemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.
PrimidoneMay increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.
ProbenecidMay increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.
PropafenoneBarbiturates may decrease the serum concentration of Propafenone.
PyridoxineMay increase the metabolism of Barbiturates. Apparent in high pyridoxine doses (eg, 200 mg/day)
RisedronateBarbiturates may increase the metabolism of Calcium Channel Blockers.
RopiniroleCNS Depressants may enhance the sedative effect of ROPINIRole.
RotigotineCNS Depressants may enhance the sedative effect of Rotigotine.
RufinamideMay enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.
SecobarbitalMay increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.
SorafenibAcetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen.
SuvorexantCNS Depressants may enhance the CNS depressant effect of Suvorexant.
TapentadolMay enhance the CNS depressant effect of CNS Depressants.
TeniposideBarbiturates may decrease the serum concentration of Teniposide.
ThalidomideCNS Depressants may enhance the CNS depressant effect of Thalidomide.
UlipristalBarbiturates may decrease the serum concentration of Ulipristal.
VerapamilBarbiturates may increase the metabolism of Calcium Channel Blockers.
VoriconazoleBarbiturates may decrease the serum concentration of Voriconazole.
ZolpidemCNS Depressants may enhance the CNS depressant effect of Zolpidem.
Food InteractionsNot Available

Targets

1. Gamma-aminobutyric acid receptor subunit alpha-1

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit alpha-1 P14867 Details

References:

  1. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. Pubmed
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. Pubmed
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. Pubmed
  4. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. Pubmed
  5. Cutrer FM, Mitsikostas DD, Ayata G, Sanchez del Rio M: Attenuation by butalbital of capsaicin-induced c-fos-like immunoreactivity in trigeminal nucleus caudalis. Headache. 1999 Nov-Dec;39(10):697-704. Pubmed
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  7. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  8. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

2. Gamma-aminobutyric acid receptor subunit alpha-2

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit alpha-2 P47869 Details

References:

  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. Pubmed
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. Pubmed

3. Gamma-aminobutyric acid receptor subunit alpha-3

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit alpha-3 P34903 Details

References:

  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. Pubmed
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. Pubmed

4. Gamma-aminobutyric acid receptor subunit alpha-4

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit alpha-4 P48169 Details

References:

  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. Pubmed

5. Gamma-aminobutyric acid receptor subunit alpha-5

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit alpha-5 P31644 Details

References:

  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. Pubmed
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. Pubmed

6. Gamma-aminobutyric acid receptor subunit alpha-6

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit alpha-6 Q16445 Details

References:

  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. Pubmed
  2. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. Pubmed

7. Neuronal acetylcholine receptor subunit alpha-4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Neuronal acetylcholine receptor subunit alpha-4 P43681 Details

References:

  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. Pubmed
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. Pubmed
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. Pubmed

8. Neuronal acetylcholine receptor subunit alpha-7

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Neuronal acetylcholine receptor subunit alpha-7 P36544 Details

References:

  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. Pubmed
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. Pubmed
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. Pubmed

9. Glutamate receptor 2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Glutamate receptor 2 P42262 Details

References:

  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. Pubmed
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. Pubmed

10. Glutamate receptor ionotropic, kainate 2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Glutamate receptor ionotropic, kainate 2 Q13002 Details

References:

  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. Pubmed
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. Pubmed

11. GABA-A receptor (anion channel)

Kind: protein group

Organism: Human

Pharmacological action: yes

Actions: positive allosteric modulator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit alpha-1 P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2 P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3 P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4 P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5 P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6 Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1 P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2 P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3 P28472 Details
Gamma-aminobutyric acid receptor subunit delta O14764 Details
Gamma-aminobutyric acid receptor subunit epsilon P78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1 Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2 P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3 Q99928 Details
Gamma-aminobutyric acid receptor subunit pi O00591 Details
Gamma-aminobutyric acid receptor subunit theta Q9UN88 Details

References:

  1. ChEMBL Compound Report Card (Accessed December 2013)

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2013 16:23